Pharmaceutical Technology

AUGUST 24, 2022

More than three decades ago, scientists at the National Cancer Institute began exploring ways to fight cancer using the patient’s immune system. The global immunotherapy market, which includes CAR T-cell therapy, adoptive cell therapies, checkpoint inhibitors, monoclonal antibodies, and other immunotherapies, is expected to grow by 10.1%

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

The Pharma Data

NOVEMBER 20, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Production Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company’s (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.

Antibody 52

Antibody Medicine Manufacturing Trials 52

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

JANUARY 26, 2021

. “These exciting results, which replicate positive Phase 2 data in a much larger set of patients, add valuable clinical evidence about the role neutralizing antibodies can play in fighting this pandemic. Lilly’s chief scientific officer and president of Lilly Research Laboratories. have reached record highs.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

XTalks

FEBRUARY 12, 2021

1.351 variant, researchers found that neutralization of the virus by sera containing AZD1222 vaccine-induced antibodies was significantly lower compared with the original strain of SARS-CoV-2. Scientists estimate that the problematic, more contagious B.1.351

Vaccine 105

Vaccine Vaccination Trials Antibody 105

The Pharma Data

OCTOBER 28, 2020

government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The supply of Lilly’s antibody therapy is expected to increase substantially beginning in Q1 2021, as additional manufacturing resources come online throughout the year. INDIANAPOLIS, Oct.

Antibody 40

Antibody Medicine Manufacturing Scientist 40

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

pharmaphorum

FEBRUARY 24, 2022

Monoclonal antibodies have made an important contribution to the treatment of COVID-19. Thanks to the great work of the scientists at the Wyss Institute, we now have compelling evidence that azeliragon may have the potential to prevent severe COVID-19 illness in the form of a once-a-day pill. said Cantex CEO Stephen Marcus.

Licensing 64

Licensing Licensing Development Drugs 64

XTalks

JANUARY 14, 2021

As scientists learn more about the new B.1.1.7 This variant contains the same N501Y mutation as B.1.1.7 However, it has a more concerning E484K mutation that may lower antibody recognition. A preliminary study has shown that the BioNTech/Pfizer vaccine elicits similar antibody titers against the B.1.1.7 In addition to B.1.1.7,

Genetics 98

Genetics Genomics Genome Protein 98

The Pharma Data

NOVEMBER 21, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. government allocation program. Regeneron Pharmaceuticals, Inc.

Antibody 40

Antibody Production Clinical Trials Clinical Trials 40

The Pharma Data

DECEMBER 5, 2020

NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. These allow for the creation of bispecific antibodies that closely resemble natural human antibodies with no linkers or artificial sequences.

Antibody 40

Antibody Production Trials Medicine 40

The Pharma Data

JANUARY 26, 2021

It contains a set of mutations that may affect its ability to be recognized by immune system antibodies, according to the U.S. They emerged in the United Kingdom, South Africa, and Brazil, and scientists believe they spread more easily than the original virus, the AP reported. Centers for Disease Control and Prevention.

Containment 52

Containment Antibody Scientist Research 52

The Pharma Data

AUGUST 18, 2020

Virus-neutralizing antibody discovery. Notice to Investors Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding development of potential preventive and treatment regimens for COVID-19.

Development 52

Development Research Containment Production 52

Advarra

MARCH 10, 2023

Red blood cells contain hemoglobin, a protein that carries oxygen. Understanding SCD According to the Centers for Disease Control and Prevention (CDC) , SCD, also known as sickle cell anemia, is “a group of inherited red blood cell disorders. While the exact number is unknown, SCD affects approximately 100,000 Americans.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Doctors 98

XTalks

JANUARY 5, 2021

These include monoclonal antibody drugs, which are attractive therapeutic agents owing to their targeted specificity. Eli Lilly’s bamlanivimab and Regeneron’s monoclonal antibody cocktail REGEN-COV2 which consists of two monoclonal antibodies, casirivimab and imdevimab, were approved in 2020 for use in the treatment of COVID-19 patients.

Life Science 98

Life Science Clinical Trials Clinical Trials Trials 98

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc. Cohort 3: patients on mechanical ventilation.

Production 52

Production Antibody Manufacturing Trials 52

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. 2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. Pfizer’s total global revenue from Paxlovid was $18.93 billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

APRIL 7, 2023

Scientists estimate that over 80% of all known proteins associated with diseases cannot be targeted by conventional small-molecule drugs or antibody-based drugs. That is why, in recent years, cyclic peptides have become a very active research area. In principle, these compounds can achieve the fine balance required of modern drugs.

Drugs 40

Drugs Protein Bioavailability Research 40

The Pharma Data

MARCH 16, 2021

This research use only laboratory test can be used to help scientists track mutation prevalence and to assess any potential impact on diagnostics, vaccines and therapeutics, providing crucial insight for healthcare systems in making appropriate measures to combat COVID-19. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1).

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

The Pharma Data

FEBRUARY 1, 2021

The variant is perhaps the most worrisome to public health experts, because it seems to have some ability to evade COVID-19 antibody treatments or vaccines. 1.351 variant, first identified in South Africa in December, is considered by scientists to be even more worrisome than the more widely publicized British variant.

Nurses 52

Nurses Vaccination Vaccine Trials 52

The Pharma Data

JANUARY 14, 2021

Bemarituzumab (anti-FGFR2b) is a first-in-class targeted antibody that blocks fibroblast growth factors (FGFs) from binding and activating FGFR2b, inhibiting several downstream pro-tumor signaling pathways and potentially slowing cancer progression. Securities and Exchange Commission, including the “Risk Factors” contained therein.

Trials 52

Trials HR Containment Development 52

The Pharma Data

AUGUST 19, 2020

The transaction will include full global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. In autoantibody-driven diseases, the body’s antibodies attack or damage its own proteins, cells and tissues, often with devastating consequences.

Production 52

Production Dermatology Development Containment 52

The Pharma Data

MAY 4, 2021

Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function.

Antibody 52

Antibody Medicine FDA Approval Licensing 52

The Pharma Data

AUGUST 19, 2020

The transaction will include full global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. In autoantibody-driven diseases, the body’s antibodies attack or damage its own proteins, cells and tissues, often with devastating consequences.

Production 40

Production Dermatology Development Containment 40

The Pharma Data

DECEMBER 27, 2020

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R R on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. R on macrophages.

Production 52

Production Drugs Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 23, 2020

The Midwest and Rocky Mountains are struggling to contain major outbreaks, while new hot spots are emerging in other parts of the country. The FDA also has given emergency authorization to using the blood plasma of survivors, and two companies are seeking emergency authorization for experimental antibody drugs.

Drugs 52

Drugs FDA Approval Doctor Doctors 52

The Pharma Data

OCTOBER 24, 2020

” The Midwest and Rocky Mountains are struggling to contain major outbreaks, while new hot spots are emerging in other parts of the country, The New York Times reported. CDC scientists had been discussing the new guidance for several weeks, said an agency official who spoke on the condition of anonymity, the Post reported.

Drugs 52

Drugs FDA Approval Doctor Doctors 52

The Pharma Data

DECEMBER 21, 2020

The selective destruction of such proteins is expected to have multiple advantages over classical drugs such as inhibitors and antibodies for the development of novel therapeutics against a broad range of diseases. For more information, please visit: [link]. LinkedIn: @CaptorTherapeutics | Twitter: @CaptorTherapeu1.

Drugs 40

Drugs Protein Development Production 40

The Pharma Data

NOVEMBER 5, 2020

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus. Evinacumab , an antibody to ANGPTL3.

Sales 40

Sales Production Manufacturing Antibody 40

The Pharma Data

AUGUST 11, 2020

Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Follow patients closely for evidence of transplant-related complications and intervene promptly.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Follow patients closely for evidence of transplant-related complications and intervene promptly.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

XTalks

OCTOBER 16, 2020

Inmazeb is a combination of three different antiviral monoclonal antibodies. The three monoclonal antibodies contained in Inmazeb are of similar structure; however, they bind to different, non-overlapping epitopes simultaneously on a glycoprotein found on the surface of the Ebola virus. Targeted Antiviral Treatment.

Antibody 98

Antibody Drugs Clinical Trials Clinical Trials 98

The Pharma Data

OCTOBER 14, 2020

“Decades of investment in our VelociSuite® rapid response technologies, the dedication of world-class scientists, and the courageous contributions of healthcare providers and patients, together with remarkable cooperation between leading international health organizations and governments, have led to this important moment.

FDA Approval 52

FDA Approval Antibody Production Trials 52

The Pharma Data

DECEMBER 20, 2020

. PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS. ” ABOUT ALLOY THERAPEUTICS Alloy Therapeutics is a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all.

Antibody 52

Antibody In-Vivo In-Vitro Scientist 52

pharmaphorum

OCTOBER 31, 2022

s Inmazeb (consisting of the monoclonal antibodies atoltivimab, maftivimab, and odesivimab-ebgn). Indeed, Regeneron believes that the success with Ebola could potentially have ushered in “a new era in which monoclonal antibodies could be used to fight viral diseases and global pandemics.”.

Production 52

Production FDA Approval Antibody Gene 52